Discover 1 curated intelligence briefings related to this specific topic.
The global conversation around Semaglutide is shifting. No longer just a tool for weight loss or glycemic control, the metabolic powerhouse is now being targeted at the stubborn architecture of liver fibrosis, marking a strategic pivot in how we treat metabolic dysfunction-associated steatohepatitis (MASH).
